915769-50-5

Hazard Information

Questions And Answer

• Anticancer drugs

  Dovitinib is an orally active small molecule multi-targeted tyrosine kinase inhibitor which can act directly on the tumor cells and provide nutritional support for blood vessels and stromal tumor cells, it has inhibition effect on a variety of growth factors such as VEGFR1-3, FGFR1-3, PDGFRB, e-KIT, Ret, TraA and csf-1. At present, Dovitinib is in clinical trail phase III ,clinical studies show that it has significant therapeutic effect on breast cancer, urinary tract carcinoma, prostate cancer, multiple myeloma, melanoma. With the development of clinical researches, cancer treatment is expected to expand its scope.
  Dovitinib performs its anti-tumor effects by anti-angiogenic activity and anti-proliferative survival activity . The drug is used for inoperable/local treatment of advanced hepatocellular carcinoma patients,it requires the lesion diameter greater than 1cm , blood, liver function is good, physical condition is good ,patients do not receive any systemic therapy (allow surgery 4 weeks outside and radiotherapy and intervention ).
  Preparation: use 5-chloro-2-nitroaniline and N-methyl piperazine as raw materials,after substitution,and reduction, form a ring with β-ethoxy-β-imino-propionate hydrochloride .Finally,after cyclization with 2-amino-6-fluorobenzonitrileto, generate Dovitinib , a total yield of 44.1%.
  The above information is edited by the chemicalbook of Tian Ye. ;

Spectrum Detail

Supplier

Related Products